- Home
- OTLY vs CRVS Comparison
OTLY vs CRVS Comparison
Compare OTLY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- CRVS
- Stock Information
- Founded
- OTLY 1994
- CRVS 2014
- Country
- OTLY Sweden
- CRVS United States
- Employees
- OTLY N/A
- CRVS N/A
- Industry
- OTLY Packaged Foods
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- CRVS Health Care
- Exchange
- OTLY Nasdaq
- CRVS Nasdaq
- Market Cap
- OTLY 518.0M
- CRVS 459.0M
- IPO Year
- OTLY 2021
- CRVS 2016
- Fundamental
- Price
- OTLY $11.83
- CRVS $8.60
- Analyst Decision
- OTLY Buy
- CRVS Strong Buy
- Analyst Count
- OTLY 5
- CRVS 4
- Target Price
- OTLY $19.00
- CRVS $13.75
- AVG Volume (30 Days)
- OTLY 90.6K
- CRVS 1.0M
- Earning Date
- OTLY 10-29-2025
- CRVS 11-04-2025
- Dividend Yield
- OTLY N/A
- CRVS N/A
- EPS Growth
- OTLY N/A
- CRVS N/A
- EPS
- OTLY N/A
- CRVS N/A
- Revenue
- OTLY $842,996,000.00
- CRVS N/A
- Revenue This Year
- OTLY $4.06
- CRVS N/A
- Revenue Next Year
- OTLY $4.85
- CRVS N/A
- P/E Ratio
- OTLY N/A
- CRVS N/A
- Revenue Growth
- OTLY 3.63
- CRVS N/A
- 52 Week Low
- OTLY $6.00
- CRVS $2.54
- 52 Week High
- OTLY $18.84
- CRVS $9.55
- Technical
- Relative Strength Index (RSI)
- OTLY 29.33
- CRVS 59.91
- Support Level
- OTLY $14.52
- CRVS $8.69
- Resistance Level
- OTLY $12.60
- CRVS $9.22
- Average True Range (ATR)
- OTLY 0.76
- CRVS 0.59
- MACD
- OTLY -0.30
- CRVS 0.03
- Stochastic Oscillator
- OTLY 3.34
- CRVS 70.18
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).